Accelerated Approval Granted To Opdivo in Metastatic Melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Opdivo (nivolumab) injection for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor.

This indication was granted under an accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Opdivo is sponsored by Bristol-Myers Squibb Company.

The efficacy of Opdivo was evaluated based on a single-arm, non-comparative planned interim analysis of the first 120 patients who received Opdivo with a minimum of six months follow-up in the phase III CheckMate-037 trial.

Opdivo achieved a 32 percent response rate (95% CI: 23, 41) with a dosing strength and frequency of 3 mg/kg intravenously over 60 minutes every two weeks. Three percent of patients achieved a complete response, and 28 percent achieved a partial response. Of 38 patients with responses, 33 patients had ongoing responses with durability of response ranging from 2.6+ to 10+ months, which included 13 patients with ongoing responses of six months or longer. Responses to Opdivo were demonstrated in both patients with and without BRAF mutation.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login